Brief: Prostatype Signs Deal With Cambridge Clinical Laboratories
Aug 17 (Reuters) - Prostatype Genomics AB PROGEN.ST :
* PROSTATYPE GENOMICS SIGNS AGREEMENT WITH CAMBRIDGE
CLINICAL
LABORATORIES, CCL
* THIS COOPERATION FURTHERS PROSTATYPE'S ENTRY INTO ANOTHER
PRIORITIZED MARKET, IN LINE WITH COMPANY'S STRATEGY.
Source text for Eikon: ID:nWkr7BfqzJ
Further company coverage: PROGEN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Prostatype Genomics AB
See all newsBrief: Prostatype Genomics Cannot Specify Timing For Final Medicare Decision
Brief: Prostatype Genomics Enters SEK 6.0 Mln Agreement With Vator Securities For To6
Brief: Prostatype Genomics AB H1 2026 Net Sales SEK 457,000
Brief: Prostatype Genomics Resolves On Directed Issue
Brief: Prostatype Genomics To Receive About SEK 47.4 Mln From Rights Issue